Literature DB >> 23107591

Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines.

Robert B Couch1, Robert L Atmar, Wendy A Keitel, John M Quarles, Janet Wells, Nancy Arden, Diane Niño.   

Abstract

BACKGROUND: Serum antibody to the hemagglutinin (HA) surface protein of influenza virus induced by influenza vaccination is a correlate of protection against influenza. The neuraminidase (NA) protein is also on the surface of the virus; antibody to it has been shown to impair virus release from infected cells and to reduce the intensity of influenza infections in animal models and in humans challenged with infectious virus. Recently we have shown that NA inhibiting antibody can independently contribute to immunity to naturally-occurring influenza immunity in the presence of antibody to the HA.
PURPOSE: The present study was conducted to evaluate induction of antibody to the NA and the HA by commercially available influenza vaccines.
METHODS: Healthy young adults were vaccinated with one of five commercially available trivalent inactivated vaccines or live influenza vaccine. Frequencies of serum antibody and fold geometric mean titer (GMT) increases four weeks later were measured to each of the three vaccine viruses (A/H1N1, A/H3N2, B) in hemagglutination-inhibition (HAI) and neutralization (neut) assays. Frequency and fold GMT increase in neuraminidase-inhibition (NI) antibody titers were measured to the influenza A viruses (A/H1N1, A/H3N2).
RESULTS: No significant reactogenicity occurred among the vaccinated subjects. The Fluvirin inactivated vaccine induced more anti-HA antibody responses and a higher fold GMT increase than the other inactivated vaccines but there were no major differences in response frequencies or fold GMT increase among the inactivated vaccines. Both the frequency of antibody increase and fold GMT increase were significantly lower for live vaccine than for any inactivated vaccine in HAI and neut assays for all three vaccine viruses. Afluria inactivated vaccine induced more N1 antibody and Fluarix induced more N2 antibody than the other vaccines but all inactivated vaccines induced serum NI antibody. The live vaccine failed to elicit any NI responses for the N2 NA of A/H3N2 virus and frequencies were low for the N1 of A/H1N1 virus.
CONCLUSIONS: Trivalent inactivated influenza vaccines with similar HA dosage induce similar serum anti-HA antibody responses in healthy adults. Current inactivated vaccines all induce serum anti-NA antibody to the N1 and N2 NA proteins but some are better than others for N1 or N2. The live vaccine, Flumist, was a poor inducer of either anti-HA or anti-NA serum antibody compared to inactivated vaccine in the healthy adults. In view of the capacity for contributing to immunity to influenza in humans, developing guidelines for NA content and induction of NA antibody is desirable.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23107591      PMCID: PMC3520601          DOI: 10.1016/j.vaccine.2012.10.065

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  43 in total

Review 1.  Determinants of immunity to influenza infection in man.

Authors:  C W Potter; J S Oxford
Journal:  Br Med Bull       Date:  1979-01       Impact factor: 4.291

2.  Induction of partial immunity to influenza by a neuraminidase-specific vaccine.

Authors:  R B Couch; J A Kasel; J L Gerin; J L Schulman; E D Kilbourne
Journal:  J Infect Dis       Date:  1974-04       Impact factor: 5.226

3.  Effect of neuraminidase antibody on Hong Kong influenza.

Authors:  A S Monto; A P Kendal
Journal:  Lancet       Date:  1973-03-24       Impact factor: 79.321

4.  Association of serum anti-neuraminidase antibody with resistance to influenza in man.

Authors:  B R Murphy; J A Kasel; R M Chanock
Journal:  N Engl J Med       Date:  1972-06-22       Impact factor: 91.245

5.  Further studies of the neuraminidase content of inactivated influenza vaccines and the neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations.

Authors:  A P Kendal; F M Bozeman; F A Ennis
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

6.  Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice.

Authors:  J L Schulman; M Khakpour; E D Kilbourne
Journal:  J Virol       Date:  1968-08       Impact factor: 5.103

7.  Temperature-sensitive mutants of influenza A virus: response of children to the influenza A/Hong Kong/68-ts-1(E) (H3N2) and influenza A/Udorn/72-ts-1(E) (H3N2) candidate vaccine viruses and significance of immunity to neuraminidase antigen.

Authors:  H W Kim; J O Arrobio; C D Brandt; R H Parrott; B R Murphy; D D Richman; R M Chanock
Journal:  Pediatr Res       Date:  1976-04       Impact factor: 3.756

8.  Neuraminidase content of influenza vaccines and neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations.

Authors:  A P Kendal; G R Noble; W R Dowdle
Journal:  J Infect Dis       Date:  1977-12       Impact factor: 5.226

9.  Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection.

Authors:  K R Beutner; T Chow; E Rubi; J Strussenberg; J Clement; P L Ogra
Journal:  J Infect Dis       Date:  1979-12       Impact factor: 5.226

10.  Clinical and immunologic evaluation of neuraminidase-specific influenza A virus vaccine in humans.

Authors:  P L Ogra; T Chow; K R Beutner; E Rubi; J Strussenberg; S DeMello; C Rizzone
Journal:  J Infect Dis       Date:  1977-04       Impact factor: 5.226

View more
  38 in total

Review 1.  Fast vaccine design and development based on correlates of protection (COPs).

Authors:  Cécile van Els; Siri Mjaaland; Lisbeth Næss; Julia Sarkadi; Eva Gonczol; Karen Smith Korsholm; Jon Hansen; Jørgen de Jonge; Gideon Kersten; Jennifer Warner; Amanda Semper; Corine Kruiswijk; Fredrik Oftung
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Evaluation of correlates of protection against influenza A(H3N2) and A(H1N1)pdm09 infection: Applications to the hospitalized patient population.

Authors:  Joshua G Petrie; Emily T Martin; Rachel Truscon; Emileigh Johnson; Caroline K Cheng; E J McSpadden; Ryan E Malosh; Adam S Lauring; Lois E Lamerato; Maryna C Eichelberger; Jill M Ferdinands; Arnold S Monto
Journal:  Vaccine       Date:  2019-02-07       Impact factor: 3.641

3.  Distinct cross-reactive B-cell responses to live attenuated and inactivated influenza vaccines.

Authors:  Sanae Sasaki; Tyson H Holmes; Randy A Albrecht; Adolfo García-Sastre; Cornelia L Dekker; Xiao-Song He; Harry B Greenberg
Journal:  J Infect Dis       Date:  2014-03-27       Impact factor: 5.226

Review 4.  Neuraminidase as an influenza vaccine antigen: a low hanging fruit, ready for picking to improve vaccine effectiveness.

Authors:  Maryna C Eichelberger; David M Morens; Jeffery K Taubenberger
Journal:  Curr Opin Immunol       Date:  2018-04-16       Impact factor: 7.486

5.  Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.

Authors:  Alaina J Mooney; Jon D Gabbard; Zhuo Li; Daniel A Dlugolenski; Scott K Johnson; Ralph A Tripp; Biao He; S Mark Tompkins
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

6.  Optimization of an enzyme-linked lectin assay suitable for rapid antigenic characterization of the neuraminidase of human influenza A(H3N2) viruses.

Authors:  Kim B Westgeest; Theo M Bestebroer; Monique I J Spronken; Jin Gao; Laura Couzens; Albert D M E Osterhaus; Maryna Eichelberger; Ron A M Fouchier; Miranda de Graaf
Journal:  J Virol Methods       Date:  2015-02-21       Impact factor: 2.014

7.  Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.

Authors:  Felix Broecker; Allen Zheng; Nungruthai Suntronwong; Weina Sun; Mark J Bailey; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

8.  Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine.

Authors:  Innocent N Mbawuike; Robert L Atmar; Shital M Patel; David B Corry; Patricia L Winokur; Rebecca C Brady; Wilbur H Chen; Kathryn M Edwards; C Buddy Creech; Emmanuel B Walter; Sharon E Frey; Robert B Belshe; Johannes B Goll; Heather Hill; Wendy A Keitel
Journal:  Vaccine       Date:  2015-12-04       Impact factor: 3.641

9.  Characteristics of vaccine failures in a randomized placebo-controlled trial of inactivated influenza vaccine in children.

Authors:  Sophia Ng; Michael Y Ni; Vicky Jing Fang; Dennis Kai Ming Ip; Kwok-Hung Chan; Gabriel Matthew Leung; Joseph Sriyal Malik Peiris; Benjamin John Cowling
Journal:  Pediatr Infect Dis J       Date:  2014-02       Impact factor: 2.129

10.  Comparability of neuraminidase inhibition antibody titers measured by enzyme-linked lectin assay (ELLA) for the analysis of influenza vaccine immunogenicity.

Authors:  Maryna C Eichelberger; Laura Couzens; Yonghong Gao; Min Levine; Jacqueline Katz; Ralf Wagner; Catherine I Thompson; Katja Höschler; Karen Laurie; Tian Bai; Othmar G Engelhardt; John Wood
Journal:  Vaccine       Date:  2015-12-18       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.